Business Wire

NJ-LABVANTAGE-SOLUTIONS

25.4.2022 14:02:07 CEST | Business Wire | Press release

Share
New LabVantage Forensic Navigator™ Seamlessly Manages Vast Data Flows Over the Entire Forensic Life Cycle

LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services, including purpose-built LIMS solutions that allow labs to go live faster and at a lower total cost, today announced the introduction of LabVantage Forensic NavigatorTM , an industry expert-built informatics platform designed to seamlessly manage the vast amounts of forensic evidence and data used throughout the entire criminal justice life cycle.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220425005012/en/

Forensic Navigator handles data flows in real time, from the evidence gathered at the crime scene through the ultimate resolution of the investigation. It accelerates the investigative process by streamlining, connecting, and analyzing all aspects of a criminal case, including evidence collection, property management, forensic lab analyses, medical examiner processes and reports, investigative activities, and legal proceedings. Forensic Navigator also includes critical tools to ensure quality management and regulatory compliance, in addition to forensic intelligence capabilities that allow users to gain insight from all data generated spanning investigations even across cases.

“LabVantage Forensic Navigator is a breakthrough informatics platform designed to increase the efficiency, effectiveness and accuracy of criminal justice operations,” said Mikael Hagstroem, Chief Executive Officer of LabVantage Solutions. “Forensic Navigator is built on the foundation of our industry-leading LIMS platform, but our developers went beyond those capabilities to produce a comprehensive system capable of managing and integrating the enormous amount of information generated during criminal investigations. At LabVantage we aim to bring the benefits of digital transformation to a variety of data-intensive industries, and we are proud to introduce this important new product purpose-built for the criminal justice sector, where data abounds and the stakes are so high.”

Forensic Navigator uses browser-based technology that is cloud hosted and is available in either SaaS or on-premise formats. It is a single, integrated, configurable platform that eliminates the need for customization. Forensic Navigator supports compliance with ISO17025, CALEA and other accreditations. It encompasses the entire forensic life cycle with best-in-class cybersecurity protection. Forensic Navigator’s forensics intelligence software provides insights from investigative data and is enhanced by predictive analysis through its forensic intelligence capabilities.

Robin MacDonald, PhD, Senior Product Specialist at LabVantage, spent more than a decade managing a forensic unit serving one of the largest counties in Florida. Dr. MacDonald noted, “The comprehensive data management capabilities of LabVantage Forensic Navigator would have been a huge help when I was a front-line forensic scientist at a busy law enforcement agency. In the complex, highly regulated criminal justice environment, Forensic Navigator’s ability to seamlessly manage all the evidence and data needed for investigations is a major advantage, eliminating the burden and inefficiency of implementing, maintaining, and coordinating multiple data management systems. It allows law enforcement personnel to enter data in real time, make examination requests and check status from a secure web-based portal. We offer a go-live plan that simplifies implementation and LabVantage’s track record of exceptional customer service means that expert user support is always available.”

Key advantages of LabVantage Forensic Navigator include:

  • Advanced technology - HTML5-based platform with advanced predictive analytics via forensic intelligence.
  • Browser-based - Cloud hosted and available in either SaaS or on-premise formats.
  • Configurable - With industry best practices, including data integrity and cybersecurity protection.
  • Online portal - For evidence pre-log, exam requests, status updates, and released reports.
  • Dashboards - View all key performance indicators at a glance.
  • Instruments - Integration and interface with most networkable instruments.
  • Collaboration - Enables rapid access to shared data. Duplicative entry is never needed.
  • Chain of custody - Includes person-to-person and person-to-secure-location transfers, with reporting options.
  • Case management – Facilitates organizing all aspects of the case.
  • Crime scene – Upload images and videos, capture scene-processing activities, and generate reports.
  • Property management – Easily locate evidence and manage disposition activities.
  • Medical examiner - Document external and autopsy observations, track next-of-kin, capture interviews.
  • Laboratory – Track evidence through intake, examination assignment, testing, and reporting.
  • Electronic lab notebook - Tracking support throughout the entire analytical life cycle.
  • Reagents - Manage reagents, standards, and other laboratory consumables.
  • Forensic intelligence - Pool siloed data for rapid resolution of cases and confidence in results.
  • SDMS - Collect and secure files maintained throughout the lab with full traceability and search functions.

For more information on LabVantage Forensic Navigator click here or email info@labvantage.com .

About LabVantage Solutions
A recognized leader in enterprise laboratory software solutions, LabVantage Solutions dedicates itself to improving customer outcomes by transforming data into knowledge. The LabVantage informatics platform is highly configurable, integrated across a common architecture, and 100% browser-based to support hundreds of concurrent users. Deployed on-premise, via the cloud, or SaaS, it seamlessly interfaces with instruments and other enterprise systems – enabling true digital transformation. The platform consists of the most modern laboratory information management system (LIMS) available, integrated electronic laboratory notebook (ELN), laboratory execution system (LES), scientific data management system (SDMS), and advanced analytics; and, for healthcare settings, a laboratory information system (LIS). We support more than 1500 global customer sites in the life sciences, pharmaceutical, medical device, biobank, food & beverage, consumer packaged goods, oil & gas, genetics/diagnostics, and healthcare industries. Headquartered in Somerset, NJ, with global offices, LabVantage has offered its comprehensive portfolio of products and services to enable customers to innovate faster in the R&D cycle, improve manufactured product quality, achieve accurate record-keeping, and comply with regulatory requirements for four decades. For more information, visit labvantage.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/labvantage

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release

Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye